Avenzo Therapeutics announces $150M Oversubscribed Financing to Advance Emerging Oncology Pipeline

San Diego, CA, March 26, 2024 (Business Wire) -- Avenzo Therapeutics concludes an oversubscribed $150 million Series A-1 financing round, bringing total capital raised to $347 million since its founding in August 2022. Led by prominent investors including NEA, Deep Track Capital, and Sofinnova Investments, this funding underscores Avenzo's commitment to advancing next-generation oncology therapeutics. Jakob Dupont, M.D., Executive Partner at Sofinnova Investments, will join Avenzo's Board of Directors, enhancing the company's strategic leadership.

Read full article here.